Royal Bank of Canada’s Drugs Made In America Acquisition II Corp Right DMIIR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1K Hold
6,998
– – ﹤0.01% 7318
2026
Q1
$1K Sell
6,998
-51,002
-88% -$5.79K ﹤0.01% 7016
2025
Q4
$8K Buy
+58,000
New +$8.28K ﹤0.01% 6550

Other funds holding DMIIR

Royal Bank of Canada's DMIIR Position: Q2 2026 in Review

Royal Bank of Canada held its Drugs Made In America Acquisition II Corp Right (DMIIR) position steady in Q2 2026 at 6,998 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #7318.

Royal Bank of Canada first reported a position in DMIIR in Q4 2025 and has held it in 3 quarters since. The position peaked at $8K in Q4 2025. 62 funds tracked by Wall St. Rank hold DMIIR as of Q2 2026.

  • Royal Bank of Canada held 6,998 shares of Drugs Made In America Acquisition II Corp Right worth $1K as of Q2 2026.
  • Royal Bank of Canada left its Drugs Made In America Acquisition II Corp Right share count unchanged in Q2 2026.
  • Drugs Made In America Acquisition II Corp Right made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #7318 holding.
  • Royal Bank of Canada first reported a position in Drugs Made In America Acquisition II Corp Right in Q4 2025 and has held it in 3 quarters since.
  • Royal Bank of Canada's Drugs Made In America Acquisition II Corp Right position peaked at $8K in Q4 2025.
  • 62 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Right as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.